NICE cirrhosis guideline

1 Comment

Diagnosis

Be aware that there is an increased risk of cirrhosis in people who:
- have hepatitis B virus infection
- have hepatitis C virus infection
- misuse alcohol
- are obese (BMI of 30 kg/m2 or higher)
- have type 2 diabetes
Also see the NICE guidelines on: non-alcoholic fatty liver disease (NAFLD), alcohol-use disorders: diagnosis and management of physical complications, alcohol-use disorders: prevention, alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence, type 2 diabetes in adults, obesity and hepatitis B (chronic)
Discuss with the person the accuracy, limitations and risks of the different tests for diagnosing cirrhosis
Offer transient elastography to diagnose cirrhosis for:
- people with hepatitis C virus infection
- men who drink over 50 units of alcohol per week and women who drink over 35 units of alcohol per week and have done so for several months
- people diagnosed with alcohol-related liver disease
Offer either transient elastography or acoustic radiation force impulse imaging (whichever is available) to diagnose cirrhosis for people with NAFLD and advanced liver fibrosis (as diagnosed by a score of 10.51 or above using the enhanced liver fibrosis [ELF] test). Also see the assessment for advanced liver fibrosis section in NICE's NAFLD guideline
Consider liver biopsy to diagnose cirrhosis in people for whom transient elastography is not suitable
For recommendations on diagnosing cirrhosis in people with hepatitis B virus infection, see the assessment of liver disease in secondary specialist care section in NICE's hepatitis B (chronic) guideline
Do not offer tests to diagnose cirrhosis for people who are obese (BMI of 30 kg/m2 or higher) or who have type 2 diabetes, unless they have NAFLD and advanced liver fibrosis (as diagnosed by a score of 10.51 or above using the ELF test). Also see the assessment for advanced liver fibrosis section in NICE's NAFLD guideline
Ensure that healthcare professionals who perform or interpret non‑invasive tests are trained to do so
Do not use routine laboratory liver blood tests to rule out cirrhosis
Refer people diagnosed with cirrhosis to a specialist in hepatology
Offer retesting for cirrhosis every 2 years for:
- people diagnosed with alcohol-related liver disease
- people with hepatitis C virus infection who have not shown a sustained virological response to antiviral therapy
- people with NAFLD and advanced liver fibrosis
For recommendations on reassessing liver disease in hepatitis B virus infection, see the assessment of liver disease in secondary specialist care section in NICE's hepatitis B (chronic) guideline

Monitoring

Risk of complications

Refer people who have, or are at high risk of, complications of cirrhosis to a specialist hepatology centre
Calculate the Model for End‑Stage Liver Disease (MELD) score every 6months for people with compensated cirrhosis
Consider using a MELD score of 12 or more as an indicator that the person is at high risk of complications of cirrhosis

Hepatocellular carcinoma

Offer ultrasound (with or without measurement of serum alpha‑fetoprotein) every 6 months as surveillance for hepatocellular carcinoma (HCC) for people with cirrhosis who do not have hepatitis B virus infection
For people with cirrhosis and hepatitis B virus infection, see the surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B section in NICE's hepatitis B (chronic) guideline
Do not offer surveillance for HCC for people who are receiving end of life care

Oesophageal varices

After a diagnosis of cirrhosis, offer upper gastrointestinal endoscopy to detect oesophageal varices
For people in whom no oesophageal varices have been detected, offer surveillance using upper gastrointestinal endoscopy every 3 years

Managing complications

Offer endoscopic variceal band ligation for the primary prevention of bleeding for people with cirrhosis who have medium to large oesophageal varices
Offer prophylactic intravenous antibiotics for people with cirrhosis who have upper gastrointestinal bleeding
Review intravenous antibiotics prescriptions in line with the prescribing intravenous antimicrobials section in NICE's antimicrobial stewardship guideline
Consider a transjugular intrahepatic portosystemic shunt for people with cirrhosis who have refractory ascites
Offer prophylactic oral ciprofloxacin or norfloxacin^* for people with cirrhosis and ascites with an ascitic protein of 15 g/litre or less, until the ascites has resolved

Footnote

*At the time of publication (July 2016), neither ciprofloxacin nor norfloxacin had a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Good practice in prescribing medicines —guidance for doctors for further information.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

First included: 06 July 2016.

Read the Guidelines in Practice article Identifying people at risk of liver disease progression is crucial for more information on implementing NICE Guideline (NG) 49 on Non-alcoholic fatty liver disease (NAFLD): assessment and management and NG50 on Cirrhosis in over 16s: assessment and management